Journal of Clinical Oncology · 2006 · 173 citations · 50 references
MedicineOncologyPharmacologyChemotherapyEpigeneticsMolecular OncologyBrain TumorsEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsPediatric Brain TumorsPediatric Neuro-oncologyDna MethyltransferasesEpigenetic Gene SilencingEpigenetic SilencingGlioma ChemotherapyImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersPrognostic Factors Analysis
PURPOSE: O6-methylguanine-DNA methyltransferase (MGMT) functions to counteract the cytotoxic effects of alkylating agents, such as nitrosoureas, which play a central role in the treatment of childhood malignant gliomas. Epigenetic silencing of MGMT has been associated with prolonged survival in adults with malignant gliomas, although the association between MGMT expression status and outcome in pediatric malignant gliomas has not been defined. METHODS: We examined the association between MGMT expression and survival duration using tumor samples from the Children's Cancer Group 945 study, the largest randomized trial for childhood malignant gliomas completed to date. All patients received alkylator-based chemotherapy as a component of adjuvant therapy. Archival histopathologic material yielded tissue of sufficient quality for immunohistochemical assessment of MGMT expression status in 109 specimens. RESULTS: Twelve of the 109 samples demonstrated overexpression of MGMT compared with normal brain. Five-year progression-free survival was 42.1% +/- 5% in the 97 patients whose tumors had low levels of MGMT expression versus 8.3% +/- 8% in the 12 patients whose tumors overexpressed MGMT (P = .017, exact log-rank test). The association between MGMT overexpression and adverse outcome remained significant after stratifying for institutional histologic diagnosis (eg, anaplastic astrocytoma or glioblastoma multiforme), as well as age, amount of residual tumor, and tumor location. CONCLUSION: Overexpression of MGMT in childhood malignant gliomas is strongly associated with an adverse outcome in children treated with alkylator-based chemotherapy, independently of a variety of clinical prognostic factors.
50
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
S M Hsu, Laurence Raine, Herbert Fanger · Journal of Histochemistry & Cytochemistry · 1981 · 14.3K citations · Full text
The Statistical Analysis of Failure Time Data.
Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice · Biometrics · 1981 · 10K citations
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
Introduction to Statistical Analysis.
V. V. Latshaw, W. J. Dixon, Frank J. Massey · American Mathematical Monthly · 1957 · 5.1K citations